| Financial Information Relating to Reportable Segments |
Following is financial information relating to the Company’s
reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Quarter Ended
December 31, |
|
|
Six Months Ended
December 31, |
|
| |
|
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
70,557 |
|
|
$ |
69,628 |
|
|
$ |
143,747 |
|
|
$ |
139,131 |
|
|
Clinical Controls
|
|
|
13,460 |
|
|
|
5,455 |
|
|
|
25,938 |
|
|
|
10,977 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net sales
|
|
$ |
84,017 |
|
|
$ |
75,083 |
|
|
$ |
169,685 |
|
|
$ |
150,108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
36,618 |
|
|
$ |
36,883 |
|
|
$ |
75,996 |
|
|
$ |
73,877 |
|
|
Clinical Controls
|
|
|
1,783 |
|
|
|
2,148 |
|
|
|
4,068 |
|
|
|
4,251 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before income taxes
|
|
|
38,401 |
|
|
|
39,031 |
|
|
|
80,064 |
|
|
|
78,128 |
|
|
Unallocated corporate expenses and equity method investee
losses
|
|
|
(2,183 |
) |
|
|
(1,585 |
) |
|
|
(4,192 |
) |
|
|
(2,696 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings before income taxes
|
|
$ |
36,218 |
|
|
$ |
37,446 |
|
|
$ |
75,872 |
|
|
$ |
75,432 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|